The urokinase plasminogen activator system as a novel target for tumour therapy

Fibrinolysis and Proteolysis

Volumn 14, Issue 2-3, 2000, Pages 114-132

  Schmitt, M ^a,g   Wilhelm, O G ^b   Reuning, U ^a   Kruger A ^c   Harbeck, N ^a   Lengyel, E ^a   Graeff, H ^a   Gansbacher B ^c   Kessler, H ^d   Burgle M ^b   Sturzebecher J ^e   Sperl, S ^f   Magdolen, V ^a  

^a Klin Forschergruppe der Frauenkl   (Germany)

^b Wilex Biotechnology GmbH   (Germany)

^c Inst Experimentelle Onkologie T   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^f MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; TOXIN; UROKINASE; UROKINASE RECEPTOR; VIRUS VECTOR;

CANCER; CANCER RECURRENCE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; GENE THERAPY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

EID: 12944328659     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1054/fipr.2000.0079     Document Type: Review

References (180)

1. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumour invasion and metastasis (review). Int J Oncol 1998; 13: 893-906.
2. Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 285-296.
3. Duffy MJ. Cancer metastasis: biological and clinical aspects. Ir J Med Sci 1998; 167: 4-8.
4. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
5. Schmitt M, Jaenicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992; 6 (suppl 4): 3-26.
6. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111: 783-792.
7. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86-92.
8. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-1072.
9. Ploug M. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry 1998; 37: 16494-16505.
10. Ploug M, Ellis V, Dano K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 1994; 33: 8991-8997.
11. Chucholowski N, Schmitt M, Goretzki L et al. Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA). Biochem Soc Trans 1992; 20: 208-216.
12. Stephens RW, Brunner N, Jaenicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998; 52: 99-111.
13. Behrendt N, Ronne E, Dano K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler 1995; 376: 269-279.
14. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes. EMBO J 1997; 16: 2610-2620.
15. Nykjaer A, Kjoller L, Cohen RL et al. Regions involved in binding of urokinase-type-1 inhibitor complex and prourokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 1994; 269: 25668-25676.
16. Ragno P, Montuori N, Rossi G. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogenactivator inhibitor complexes with the cell surface. Eur J Biochem 1995; 233: 514-519.
17. Carriero MV, Del Vecchio S, Capozzoli M et al. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999; 59: 5307-5314.
18. Germer M, Kanse SM, Kirkegaard T et al. Kinetic analysis of integrin-dependent cell adhesion on vitronectin-the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem 1998; 253: 669-674.
19. BohuslavJ, Horejsi V, Hansmann C et al. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 1995; 181: 1381-1390.
20. Simon DI, Wei Y, Zhang L et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 2000; 275: 10228-10234.
21. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/ plasmin system. Thrombosis Haemostasis 1995; 74: 429-436.
22. Carmeliet P, Schoonjans L, Kieckens L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424.
23. Romer J, Bugge TH, Pyke C et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Medicine 1996; 2: 287-293.
24. Kirchheimer JC, CG, Binder BR. Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. Eur J Biochem 1989; 181: 103-107.
25. Kirchheimer JC, Wojta J, Christ G, Binder BR. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1987; 1: 125-128.
26. Kirchheimer JC, Wojta J, Christ G, Binder BR. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA 1989; 86: 5424-5428.
27. Rabbani SA, Desjardins J, Bell AW et al. An aminotemial fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173: 1058-1064.
28. Fischer K, Lutz V, Wilhelm O et al. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett 1998; 438: 101-105.
29. Luther T, Magdolen V, Albrecht S et al. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 1997; 150: 1231-1244.
30. Kanse SM, Benzakour O, Kanthou C, Kost C, Lijnen HR, Preissner KT. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol 1997; 17: 2848-2854.
31. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994; 126: 259-270.
32. Dumler I, Kopmann A, Weis A et al. Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 290-297
33. Dumler I, Stepanova V, Jerke U et al. Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin. Current Biology 1999; 9: 1468-1476.
34. Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998; 273: 8502-8507.
35. Stepanova V, Mukhina S, Kohler E, Resink TJ, Erne P, Tkachuk VA. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms. Mol Cell Biochem 1999; 195: 199-206.
36. Gudewicz PW, Gilboa N. Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Comm 1987; 147: 1176-1181.
37. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997; 16: 7279-7286.
38. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15: 1572-1582.
39. Curriden SA, Wang S, Rosenberg S, Loskutoff D. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release. J Cell Biol 1996; 134: 1563-1571.
40. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 224: 344-353.
41. Schwartz I, Seger D, Shaltiel S. Vitronectin. Int J Biochem Cell Biol 1999; 31: 539-544.
42. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
43. Carriero MV, Del Vecchio S, Franco P et al. Vitronectin binding to urokinase receptor in human breast cancer. Clin Cancer Res 1997; 3: 1299-1308.
44. Sidenius N, Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett 2000; 470: 40-46.
45. Lauffenburger D. Making connections count. Nature 1996; 383: 390-391.
46. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin [see comments]. Nature 1996; 383: 441-443.
47. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1563-1571.
48. Deng G, Royle G, Seiffert D, Loskutoff DJ. The PAI-1/vitronectin interaction: two cats in a bag? Thromb Haemost 1995; 74: 66-70.
49. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999; 147: 89-104.
50. Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Ronne E, Kobzik L, Chapman HA. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996; 88: 3185-3194.
51. Waltz DA, Fujita RM, Yang X et al. Nonproteolytic role for the urokinase receptor in cellular migration In vivo. Am J Respir Cell Mol Biol 2000; 22: 316-322.
52. Olivier P, Bieler G, Muller KM, Hauzenberger D, Ruegg C. Urokinase-type plasminogen activator inhibits alpha 4 beta 1 integrin-mediated T lymphocyte adhesion to fibronectin independently of its catalytic activity. Eur J Immunol 1999; 29: 3196-3209.
53. Wei Y, Lukashev M, Simon DI et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
54. Chapman HA, Wei Y, Simon DI, Waltz D. Role of urokinase receptor and caveolin in regulation of integrin signaling. Thrombosis Haemostasis 1999; 82: 291-297.
55. Yebra M, Goretzki L, Pfeifer M, Mueller BM. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 1999 Jul, 10; 1999; 250: 231-240.
56. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988; 62: 531-533.
57. Jaenicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer [letter]. Lancet 1989; 2: 1049.
58. Jaenicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991; 17: 303-312.
59. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 1999; 71: 130-135.
60. Sier CF, Stephens R, BizikJ et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998; 58: 1843-1849.
61. Pedersen N, Schmitt M, Ronne F et al. A ligand-free.; soluble urokinase-receptor is present in the ascitic fluid from patients with ovarian cancer. Journal Clinical Investigation 1993; 92: 2160-2167.
62. Masucci MT, Blasi F. The receptor for human urokinase: a potential target for anti-invasive and anti-metastatic therapy. Thromb Res Suppl 1990; 11: 49-60.
63. Conese M, Blasi F. The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haematol 1995; 8: 365-389.
64. Fazioli F, Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci 1994; 15: 25-29.
65. Tressler RJ, Pitot PA, Stratton JR et al. Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS 1999; 107: 168-173.
66. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
67. Sharp AM, Stein PE, Pannu NS et al. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 1999; 7: 111-118.
68. Harrop SJ, Jankova L, Coles M et al. The crystal structure of plasminogen activator inhibitor 2 at 2.0 A resolution: implications for serpin function. Structure Fold Des 1999; 7: 43-54.
69. Noel A, Bajou K, Masson V et al. Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. Fibrinolysis & Proteolysis 1999; 13: 220-225.
70. Ny T, Mikus P. Plasminogen activator inhibitor type-2. A spontaneously polymerizing serpin that exists in two topological forms. Adv Exp Med Biol 1997; 425: 123-130.
71. Astedt B, Lindoff C, Lecander I. Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Semin Thromb Hemost 1998; 24: 431-435.
72. Carmeliet P, Stassen JM, Schoonjans L et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-2760.
73. Bajou K, Noel A, Gerard RD et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-928.
74. Dougherty KM, Pearson JM, Yang AY, Westrick RJ, Baker MS, Ginsburg D. The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc Natl Acad Sci U S A 1999; 96: 686-691.
75. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997; 18: 415-417.
76. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer. Bull Cancer 1994; 81: 770-779.
77. Ballance DJ, Marshall JM, Cottingham IR et al. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor. Eur J Biochem 1992; 207: 177-183.
78. Jankun J. Antitumor activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro. Cancer Res 1992; 52: 5829-5832.
79. Jankun J, Keck RW, Skrzypczak-Jankun E, Swiercz R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice [published erratum appears in Cancer Res 1998 Jan 1;58(1): 179]. Cancer Res 1997; 57: 559-563.
80. Yebra M, Parry GCN, Stromblad S et al. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem 1996; 271: 29393-29399.
81. Gardsvoll H, van Zonneveld AJ, Holm A et al. Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries. FEBS Letters 1998; 431: 170-174.
82. Ke SH, Coombs GS, Tachias K, Corey DR, Madison EL. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 1997; 272: 20456-20462.
83. Muehlenweg B, Guthaus E, de Prada NA et al. Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides. Thromb Res 2000; 98: 73-81.
84. Praus M, Wauterickx K, Collen D, Gerard RD. Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Therapy 1999; 6: 227-236.
85. Sperl S, Jacob U, Arroyo de Prada N et al. (4-aminomethyl)phenylguanidine derivatives as non-peptidic highly selective inhibitors of human urokinase. X-ray crystal structure of a uPA/inhibitor complex at 1.7 a resolution. PNAS 2000; 97: 5113-5118.
86. Billstrom A, Hartley-Asp B, Lecander I, Batra S, Astedt B. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int J Cancer 1995; 61: 542-547.
87. Towle MJ, Lee A, Maduakor EC, Schwartz CE, Bridges AJ, Littlefield BA. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 1993; 53: 2553-2559.
88. Alonso DF, Farias EF, Ladeda V, Davel L, Puricelli L, Bal de Kier. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 1996; 40: 209-223.
89. Alonso DF, Tejera AM, Farias EF, Bal de Kier, Gomez DE. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Anticancer Res 1998; 18: 4499-4504.
90. Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 1995; 63: 840-845.
91. Xing RH, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997; 57: 3585-3593.
92. Swiercz R, Skrzypczak-Jankun E, Merrell MM, Selman SH, Jankun J. Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep 1999; 6: 523-526.
93. Nienaber V, Wang J, Davidson D, Henkin J. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. J Biol Chem 2000; 275: 7248.
94. Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature 1997; 387: 561.
95. Nakachi K, Suemasu K, Suga K, Takeo T, Imai K, Higashi Y. Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 1998; 89: 254-261.
96. Appella E, Blasi F. The growth factor module of urokinase is the binding sequence for its receptor. Ann N Y Acad Sci 1987; 511: 192-195.
97. Appella E, Robinson EA, Ullrich SJ et al. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1987; 262: 4437-4440.
98. Magdolen V, Rettenberger P, Koppitz M et al. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur J Biochem 1996; 237: 743-751.
99. Quax PH, Grimbergen JM, Lansink M et al. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. Arterioscler Thromb Vasc Biol 1998; 18: 693-701.
100. Burgle M, Koppitz M, Riemer C et al. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol Chem 1997; 378: 231-237.
101. Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci U S A 1994; 91: 7129-7133.
102. Ploug M, Ostergaard S, Hansen LB, Holm A, Dano K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 1998; 37: 3612-3622.
103. Gardsvoll H, Dano K, Ploug M. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis. J Biol Chem 1999; 274: 37995-38003.
104. Higazi A, Mazar A, Wang J et al. Soluble human urokinase receptor is composed of two active units. J Biol Chem 1997; 272: 5353.
105. Fabbrini MS, Carpani D, Bello-Rivero I, Soria MR. The aminoterminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated. FASEB J 1997; 11: 1169-1176.
106. Fabbrini MS, Carpani D, Soria MR, Ceriotti A. Cytosolic immunization allows the expression of preATF-saporin chimeric toxin in eukaryotic cells. FASEB J 2000; 14: 391-398.
107. Rajagopal V, Kreitman RJ. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor. J Biol Chem 2000; 275: 7566-7573.
108. Behrendt N, Ronne E, Dano K. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J Biol Chem 1993; 268: 5985-5989.
109. Drapkin PT, O'Riordan CR, Yi SM et al. Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. Journal of Clinical Investigation 2000; 105: 589-596.
110. Li H, Lu H, Griscelli F et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy 1998; 5: 1105-1113.
111. Lu H, Yeh P, Guitton JD et al. Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett 1994; 356: 56-59.
112. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A 1993; 90: 5021-5025.
113. Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 1997; 57: 3594-3599.
114. Ignar DM, Andrews JL, Witherspoon SM et al. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp 1998; 16: 9-20.
115. Min HY, Doyle LV, Vitt CR et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-2433.
116. Kobayashi H, Sugino D, She MY et al. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur J Biochem 1998; 253: 817-826.
117. Wilhelm OG, Wilhelm S, Escott GM et al. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 1999; 180: 225-235.
118. Brunner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 1999; 107: 160-167.
119. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 1994; 337: 131-134.
120. Kruger A, Soeltl R, Lutz V et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Ther 2000; 7: 292-299.
121. Colman RW, Pixley RA, Najamunnisa S et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 1997; 100: 1481-1487.
122. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611-619.
123. Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991; 51: 274-281.
124. List K, Hoyer-Hansen G, Ronne E, Dano K, Behrendt N. Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. J Immunol Methods 1999; 222: 125-133.
125. Gardsvoll H, Solberg H, Dano K, Hoyer-Hansen G. Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization. J Immunol Methods 2000; 234: 107-116.
126. Wilhelm O, Schmitt M, Hohl S, Senekowitsch R, Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995; 13: 296-302.
127. Morrissey D, O'Connell J, Lynch D, O'Sullivan GC, Shanahan F, Collins JK. Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor. Clin Exp Metastasis 1999; 17: 77-85.
128. Quattrone A, Fibbi G, Anichini E et al. Reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 1995; 55: 90-95.
129. Mohan PM, Chintala SK, Mohanam S et al. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Research 1999; 59: 3373.
130. Reuning U, Wilhelm O, Nishiguchi T, Guerrini L, Blasi F, Schmitt M. Inhibition of NF-kappa B-Rel A expression by antisense-oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucl Acids Res 1995; 23: 3887-3893.
131. Reuning U, Guerrini L, Nishiguchi T et al. Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells. Eur J Biochem 1999; 259: 143-148.
132. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988; 62: 531-533.
133. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ. Urokinase plasminogen activator and prognosis in breast cancer [letter]. Lancet 1990; 335: 108.
134. Jänicke F, Schmitt M, Hafter R et al. The urokinase-type plasminogen activator (u-PA) is a potent predictor of early relapse in breast cancer. Fibrinolysis 1990, 4: 69-78.
135. Foucre D, Bouchet C, Hacene K et al. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 1991; 64: 926-932.
136. FoekensJA, Schmitt M, van Putten WL et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-6105.
137. Spyratos F, Martin PM, Hacene K et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992; 84: 1266-1272.
138. Grondahl-Hansen J, Christensen IJ, Rosenquist C et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513-2521.
139. Yamashita J, Ogawa M, Yamashita S et al. Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 1993; 68: 524-529.
140. Foekens JA, Schmitt M, van Putten WL et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12: 1648-1658.
141. Janicke F, Pache L, Schmitt M et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994; 54: 2527-2530.
142. Foekens JA, Buessecker F, Peters HA et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55: 1423-1427.
143. Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87: 751-756.
144. Grondahl-Hansen J, Peters HA, van Putten WL et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 1079-1087.
145. Ferno M, Bendahl PO, Borg A et al. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 1996; 32A: 793-801.
146. Kim SJ, Shiba E, Kobayashi T et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res. 1998 4: 177-182.
147. Knoop A, Andreasen PA, Andersen JA et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77: 932-940.
148. Kute TE, Grondahl-Hansen J, Shao SM, Long R, Russell G, Brunner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998; 47: 9-16.
149. Tetu B, Brisson J, Lapointe H, Bernard P. Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. Hum Pathol 1998; 29: 979-985.
150. Peyrat JP, Vanlemmens L, Founder J, Huet G, Revillion F, Bonneterre J. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers. Clin Cancer Res 1998; 4: 189-196.
151. Eppenberger U, Kueng W, Eppenberger-Castori S, von Landenberg EM, Muller H. Molecular factors determine primary and secondary therapy of breast carcinoma. Ther Umsch 1997; 54: 451-456.
152. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA. Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse. J Clin Oncol. 1999; 17: 1449-1457.
153. Bouchet C, Hacene K, Martin PM et al. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999; 17: 3048-3057.
154. Harbeck N, Dettmar P, Thomssen C et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 1999; 80: 419-426.
155. Foekens JA, Peters HA, Look MP et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-643.
156. Chambers SK, Ivins CM, Carcangiu ML. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 1998; 79: 449-454.
157. Kuhn W, Schmalfeldt B, Reuning U et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999; 79: 1746-1751.
158. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase- type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994; 54: 6539-6548.
159. Hasui Y, Marutsuka K, Asada Y, Osada Y. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 1996; 47: 34-37.
160. Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer 1998; 82: 724-732.
161. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996; 78: 487-492.
162. Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 1995; 147: 114-123.
163. Pedersen H, Brunner N, Francis D et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-4675.
164. Yoshino H, Endo Y, Watanabe Y, Sasaki T. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br J Cancer 1998; 78: 833-839.
165. Choong PF, Ferno M, Akerman M et al. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 1996; 69: 268-272.
166. Nekarda H, Schmitt M, Ulm K et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54: 2900-2907.
167. Heiss MM, Allgayer H, Gruetzner KU et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med. 1995; 1: 1035-1039.
168. Heiss MM, Babic R, Allgayer H et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995; 13: 2084-2093.
169. Ganesh S, Sier CF, Heerding MM et al. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer. 1997; 75: 1793-1801.
170. Maeda K, Chung YS, Sawada T, Kato Y, Ogawa Y, Nitta A, Sowa M. Expression of urokinase-type plasminogen activator and plasminogen/activator inhibitor-2 in gastric carcinoma. Gan-To- Kagaku-Ryoho. 1994; 21: 277-279.
171. Plebani M, Herszenyi L, Carraro P et al. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis 1997; 15: 418-425.
172. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival [letter]. Lancet 1994; 344: 401-402.
173. Mulcahy HE, Duffy MJ, Gibbons D et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994; 344: 583-584.
174. Ganesh S, Sier CF, Griffioen G et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54: 4065-4071.
175. Ganesh S, Sier CF, Heerding MM et al. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer 1997; 75: 1793-1801.
176. Cantero D, Friess H, Deflorin J et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997; 75: 388-395.
177. Torzewski M, Sarbia M, Verreet P et al. Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. Clin Cancer Res 1997; 3: 2263-2268.
178. Nekarda H, Schlegel P, Schmitt M et al. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 1998; 4: 1755-1763.
179. Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 2000; 156: 567-575.
180. De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 1998; 58: 2234-2239.